← Back to news
NewsFDATuesday, February 10, 2026 · February 10, 2026

FDA Grants Orphan Drug Designation for Novel Duchenne Therapy

WHY IT MATTERS

Expands treatment options for the most common Duchenne mutation type.

A novel antisense oligonucleotide targeting exon 51 skipping received orphan drug designation for Duchenne muscular dystrophy.

Read the original at FDA
FDA ApprovalBreakthrough Therapy

Related conditions

Duchenne muscular dystrophy